diseases such as amyloidosis and arrhythmogenic right ventricular cardiomyopathy were also excluded by echocardiography, computed tomography, MRI, and endomyocardial biopsy. Ethical approval was obtained from the local institutional review committee. All patients gave their informed consent when retrospective data collection started. We obtained informed consent from the bereaved family of 2 patients who died before 2010. Sustained VT was defined as VT lasting >30 seconds or that requiring electric cardioversion. All patients underwent the following examinations before starting systematic treatment approach: chest roentgenography, computed tomography, serum concentrations of angiotensin-converting enzyme, echocardiography, gallium scintigraphy, and endomyocardial biopsies. We evaluated cardiac sarcoidosis activity according to gallium scintigraphy; abnormal gallium accumulation in the myocardium indicated the early phase of cardiac sarcoidosis, and no myocardial accumulation of gallium indicated the advanced phase. 9 Gallium uptake was evaluated by a radiologist blinded to the disease condition. Endomyocardial biopsy was performed from right ventricular septum. We took 2 or 3 samples in each patient.
Management of VT
An implantable cardioverter-defibrillator (ICD) was implanted in patients with sustained VTs unless they refused. All patients were initially treated with corticosteroid and antiarrhythmic agents unless they refused to take them ( Figure 1 ). The selection of antiarrhythmic agents depended on the physician's decision. The predominant antiarrhythmic agent used in this study was amiodarone administered at a maintenance dose of 100 to 200 mg/d. Therapy with corticosteroids followed the recommendations of the Japanese guidelines. 10 Specifically, corticosteroid therapies were started at an initial dose of 30 mg/d and continued for 4 weeks, followed by gradual decrease by 5 mg/d every 2 to 4 weeks until a maintenance dose of 5 to 10 mg/d was achieved. Patients undergoing RFCA before medication, including corticosteroid and antiarrhythmic agents, were excluded from this study because we could not distinguish the efficacy of RFCA from that of medication. If VT recurred even while on antiarrhythmic and corticosteroid therapy, an RFCA procedure was then attempted (Figure 1 ). Maintenance doses of corticosteroid and antiarrhythmic agents were continued after RFCA.
Electrophysiological Study and RFCA
We performed a standard electrophysiological study in the fasting, unsedated state. The mapping and ablation procedure was performed with an electroanatomic mapping system (CARTO, Biosense Webster, Diamond Bar, CA) with a NaviStar or ThermoCool catheter (Biosense Webster).
Programmed ventricular stimulation was performed using up to triple extrastimuli at drive cycle lengths of 600 and 400 ms with 10-ms extrastimulus decrement until 200 ms or ventricular refractory period was reached. Rapid burst pacing was also performed to induce non-re-entry VT.
We classified monomorphic sustained VT as Purkinje-related VT, whose circuit seemed to be closely associated with the Purkinje system including bundle branch re-entry, or scar-related VT, in which the VT circuit was within or adjacent to a scar area such as a ventricular akinetic/hypokinetic area. Purkinje involvement was proven by the finding that Purkinje potentials were observed during sinus rhythm (except in 1 patient with complete atrioventricular block) and always preceded VT-QRS onset by at least >20 ms at the successful RFCA site. The re-entry mechanism of VTs was defined in patients in whom the VT was inducible by programmed ventricular stimulation and if entrainment with fusion could be demonstrated; otherwise, the mechanism was defined as non-re-entry. We considered sustained VT as a bundle branch re-entry based on the following findings: (1) the H-V interval during VT was longer than during sinus rhythm, (2) the re-entry circuit propagated down the right bundle branch and up the left bundle branch, and (3) during spontaneous change in cycle length, changes in the H-H interval preceded and predicted changes in the V-V interval. 11 We could not assess the classification of VT in 23 patients in whom medical therapy successfully suppressed VT because they did not undergo electrophysiological study.
If hemodynamically stable monomorphic VTs could be induced, pacing was performed to entrain the VTs. We also attempted to map the VT activation sequences to clarify the VT circuit. For hemodynamically unstable VTs, pace mapping was performed at sites where the Purkinje potential was recorded for Purkinje-related VT and at low-voltage areas for scar-related VT.
RFCA was performed using the power control mode with a target power output of 30 to 40 W and maximum temperature of 42°C while using the ThermoCool irrigated catheter and 40 to 50 W and 58°C while using the Navistar nonirrigated catheter. Radiofrequency energy was delivered at the sites where concealed entrainment, the earliest presystolic potential, and good pace mapping could be obtained. An isthmus of the induced VT was defined as an excellent pace-map site with various stimulus-QRS intervals. 12, 13 A linear ablation was created to abolish the isthmus of the induced VT. Programmed ventricular stimulation was repeated using up to triple extrastimuli without isoproterenol infusion at the end of RFCA. Acute RFCA success was defined as the absence of any inducible sustained ventricular tachyarrhythmias at the end of the ablation procedure.
Follow-Up and Definition of Recurrence
Patients were followed at 2 weeks after the RFCA and then every 1 to 2 months at the outpatient clinic for >1 year. The ICD patients underwent device interrogation at each clinic visit every 6 months. A 24-hour Holter recording was obtained in the patients without an ICD at approximately yearly intervals. Long-term success was defined as the lack of any recurrence of sustained VT and appropriate ICD therapy.
Statistical Analysis
Continuous variables are expressed as mean±SD. Because of the limited sample size, nonparametric Mann-Whitney U tests were used to test for statistically significant differences in continuous variables between the study groups. All categorical variables are presented as number and percent in each group and were compared by a χ 2 analysis or Fisher exact test. Multivariable Cox proportional regression analysis was applied to explore any predictors of VT recurrences. Variables included in multivariable Cox proportional hazard models were those with P<0.1 in univariable analysis. To evaluate the predictive value of QRS duration of VT, receiver operating characteristic curve analysis was performed, and possible cutoff points were selected. All probability values were 2-sided, and a value of P<0.05 was considered statistically significant. All analyses were performed with the PASW statistics 17.0 software package (SPSS, Chicago, IL). 
Results

Patient Clinical Characteristics
All patients received antiarrhythmic agents, 34 (92%) received corticosteroid treatment, and 26 (70%) underwent ICD implantation (Table 1) . Patients not receiving corticosteroid or ICD therapy rejected these treatments. Nine (35%) of the 26 ICD patients received appropriate ICD therapy during the follow-up period.
Conduction system impairment was commonly recognized in the VT patients associated with cardiac sarcoidosis. Complete atrioventricular block was observed in 10 patients, bifascicular block in 5, left bundle branch block in 2, right bundle branch block in 5, and first-degree atrioventricular block in 6. Sustained monomorphic VT was present in 35 (95%) patients and polymorphic VT in the remaining 2 (5%) patients. The VT cycle length was 348±70 ms.
Clinical Characteristics and Outcome With Drug Therapy During Long-Term Follow-Up
During a median follow-up of 39 (interquartile range, 14-80) months, 23 (62%) patients receiving corticosteroid and antiarrhythmic agents were free from any VT episodes (Figure 1 ), of whom 19 were histologically diagnosed as having sarcoidosis based on biopsy results from endomyocardium, skin, or lung. Granuloma from endomyocardial biopsy was obtained in 11 patients, and the prevalence of positive myocardial biopsy did not differ between the patients with and without VT recurrence (P=1.0). However, left ventricular ejection fraction (P<0.01) and prevalence of gallium-67 myocardial uptake Values are reported as the mean±SD or n (%). A-V indicates atrioventricular; ACE, angiotensin-converting enzyme; CLBBB, complete left bundle branch block; CRBBB, complete right bundle branch block; ICD, implantable cardioverter-defibrillator; and VT, ventricular tachycardia.
(P<0.001) were lower in patients with VT recurrence than in those without. There was a trend toward increased prevalence of VT recurrence in patients with ICD than in those without (Table 1) . Multivariable Cox regression analysis showed that absence of gallium-67 myocardial uptake before corticosteroid therapy was an independent predictor for VT recurrence despite treatment with corticosteroid and antiarrhythmic agents (P<0.01; Table 2 ).
In 9 (24%) patients with repeat gallium scans, although normalization of the gallium scan was achieved in all patients, VT recurrence was observed in 2 of 9 patients. Among the 27 patients who took amiodarone, 2 patients stopped taking it during the follow-up period because of interstitial pneumonia in 1 patient and elevation of liver enzymes in the other patient. During the follow-up period, 1 patient without ICD died from pump failure, and the other patient with ICD died from VT storm. None of the study subjects died from sudden cardiac death.
Electrophysiological Study and Classification of VT
Among the 37 patients, 14 patients who experienced VT recurrence despite treatment with corticosteroid and antiarrhythmic agents underwent electrophysiological study and RFCA. Of 57 induced VTs in these 14 patients, 14 VTs were nonsustained and 6 showed polymorphic patterns. In the remaining 37 monomorphic sustained VTs (mean, 2.6±1.4 VT patterns per patient), 6 VTs were related to the Purkinje system in 5 patients and 31 VTs were related to scar areas in 13 patients (Table 3) . Four patients had both Purkinje-related and scar-related VTs.
Electrophysiological Characteristics of Purkinje-Related VTs
Among the 5 patients with Purkinje-related VT, 3 patients had histological confirmation of sarcoidosis. The prevalence of histologically proven sarcoidosis did not differ significantly between the patients with Purkinje-related VT and those with only scar-related VT (60% versus 33%; P=0.6). The Purkinje system was involved in 6 VTs in 5 patients, all of whom had evidence of conduction disease manifesting as atrioventricular block (1 patient), bifascicular block (2 patients), PR prolongation and right bundle branch block (1 patient), and PR prolongation (1 patient). Electrophysiological study revealed that 4 of these 5 patients had infra-Hisian conduction defects: His-ventricular block in 1 and prolonged His-ventricular interval of ≥55 ms (mean, 70±8 ms) in the remaining 3 patients. Successful sites of RFCA of the 6 Purkinje-related VTs were left anterior fascicle in 2 VTs, left posterior fascicle in 2, and right bundle branch in 2. Four of 6 VTs could be induced by programmed stimulation. The circuit of Purkinje-related VT was bundle branch re-entry in 1, micro-re-entry in 3 (Figure in 
Electrophysiological Characteristics of Scar-Related VT
Left and right ventriculography revealed ventricular akinetic/hypokinetic areas in 11 (79%) patients, of whom 10 patients had akinetic/hypokinetic area-related VTs, which were defined as those where the critical isthmus was present within the akinetic/hypokinetic area or at sites between the akinetic/hypokinetic area and tricuspid/mitral valve annulus. Septal wall thinning was recognized by echocardiography in 11 (79%) patients, and 7 of 11 patients had septal wallrelated VT. Voltage mapping revealed low-voltage areas in 8 (57%) patients. Among the 31 scar-related VTs, the critical isthmuses of VTs were located within the left ventricular free wall in 3 VTs (Figures 3 and 4) , at the perimitral valve in 6, the right ventricular free wall in 2, the peritricuspid valve in 5, the right ventricular septal wall in 8, and the left ventricular septal wall in the remaining 7 (Table 3 ). All VTs could be induced by programmed stimulation and entrained, suggesting re-entry. We successfully ablated 23 (79%) of the 29 VTs.
Electrophysiological Differences Between PurkinjeRelated and Scar-Related VTs.
The prevalence of re-entry was lower (P<0.05) in Purkinjerelated versus scar-related VT. Furthermore, QRS duration was narrower in Purkinje-related versus scar-related VT (P<0.05; Table 3 ). Receiver operating characteristic curve analysis revealed that QRS duration of <170 ms identified Purkinje-related VT with a sensitivity of 77% and specificity of 83% (area under the curve of 0.793).
The successful RFCA sites were located in the left ventricle in 20 (54%) of 37 sustained VTs. VT origin from the septal wall was observed in 19 (51%) VTs. There was no significant difference in the successful RFCA site and morphology of sustained VT between Purkinje-related and scar-related VT (Table 3) .
Clinical Outcomes After RFCA
During a median follow-up of 33 (interquartile range, 26-46) months after RFCA, 6 patients experienced VT recurrence (Figure 1 ). Among 6 patients with VT recurrence, 2 had Purkinje-related VT. There were no significant differences in age, sex, drug therapy, laboratory data, ejection fraction, gallium-67 uptake, atrioventricular conduction disturbance, wall motion abnormalities, VT type, irrigated catheter use, and inducibility at the end of RFCA between the patients with and without VT recurrence. However, the number of sustained VTs was larger in the patients with VT recurrence than in those without (3.7±1.4 versus 1.9±0.8; P<0.01). Four patients with recurrence of VT underwent a second RFCA procedure. Of those 4 patients, 3 patients whose initial ablation was directed at only scar-related VT had recurrence of scar-related VT. One patient whose initial ablation was directed at both scar-and Purkinje-related VT had an occurrence of another focal Purkinje VT.
Discussion
Major Findings
The following findings were demonstrated for the first time:
(1) absence of gallium-67 myocardial uptake at baseline was an independent predictor for VT recurrence under corticosteroid and antiarrhythmic therapy, (2) monomorphic sustained VT associated with cardiac sarcoidosis could be classified into 2 types (Purkinje-related or scar-related VT), (3) QRS duration of VT was narrower in Purkinje-related versus scar-related VTs, and (4) the number of sustained VTs was larger in the patients with VT recurrence after RFCA than in those without. The majority of patients (84%) were free of recurrent VT with this systematic treatment approach; however, the effect of therapy was not certain because of the absence of a control group.
Clinical Role of Drug Therapy for VT Associated With Cardiac Sarcoidosis
Two recent studies demonstrated the efficacy of corticosteroid therapy for ventricular arrhythmia; however, these studies did not have control group. 5, 7 Our findings that drug therapy successfully suppressed VT recurrence in approximately two thirds of patients could confirm these previous studies. 5, 7 The mechanism by which corticosteroid prevents VT is still unclear; however, one possible speculation is that epithelioid granuloma and the active inflammatory process in the ventricular myocardium could promote re-entry substrates, and suppression of the inflammatory process by corticosteroid could result in the reduction of possible substrate formation of VT. However, in the advanced stage of cardiac sarcoidosis, during which the ejection fraction is low and inflammatory activity is absent, corticosteroid therapy might have no power to modify the underlying substrate, thus resulting in VT recurrence.
Clinical Role of RFCA for VT Associated With Cardiac Sarcoidosis
A previous study demonstrated that the mechanism of VT associated with cardiac sarcoidosis was related to scar tissue.
6,7 However, we clarified for the first time that Purkinjerelated VT could also be the underlying mechanism in patients with VT associated with cardiac sarcoidosis. One plausible explanation is that epithelioid granuloma and secondary fibrosis after inflammatory processes in the myocardial tissue exist in the ventricle and cause conduction disturbances in the Purkinje system that could be responsible for the substrate of VT. Purkinje fibers are more resistant to ischemia and may develop delayed afterdepolarizations and triggered activity during acute injury, as demonstrated in an animal model of acute ischemia.
14 Purkinje-related VT associated with cardiac sarcoidosis has not been reported till date. However, Purkinje fibers are important in the initiation and perpetuation of ventricular arrhythmias in different clinical scenarios, 11, 15, 16 and elimination of these triggers by RFCA is feasible.
We also showed that the number of induced sustained VTs had prognostic value for VT recurrence after RFCA in patients with cardiac sarcoidosis. Increased numbers of induced VTs may reflect a complex arrhythmia substrate because of progression of epithelioid granulomas and the postinflammatory myocardial process in patients with cardiac sarcoidosis. 17 RFCA was performed before starting medical therapy in 9 patients, and these patients were excluded from this study. They underwent urgent or semiurgent RFCA because of their severe condition caused by VT of unknown cause. After RFCA, thorough workup revealed that the underlying disease was cardiac sarcoidosis, and medical therapy was started. Acute RFCA success was achieved in 6 (67%) of the 9 patients.
Clinical Implications
About one third of the ICD patients experienced appropriate ICD therapy. It is clear from this study that even patients with successful therapy could have recurrence; therefore, an ICD should be implanted in all patients with VT associated with cardiac sarcoidosis to prevent sudden cardiac death.
Our findings indicated that the drug therapy was less effective in patients in an advanced stage of cardiac sarcoidosis. Therefore, initiation of drug therapy as soon as possible might be required to prevent recurrence of VT associated with cardiac sarcoidosis. This is a hypothesis that warrants testing.
Approximately 7% of the patients taking amiodarone experienced drug-related side effects. Attention should be paid to the occurrence of adverse effects of amiodarone, and if possible, the dose should be decreased to minimize amiodaronerelated risks if VT recurrence is not observed for a long period. Finally, a QRS duration of <170 ms has predictive value to identify Purkinje-related VT.
Study Limitations
There are several limitations of this study. First, this was a retrospective study with a relatively short follow-up period, no control group, and small sample size. Cox regression results must be considered exploratory. Furthermore, we could have underestimated the occurrence of VT in patients without ICD. Therefore, further prospective randomized studies with a larger number of patients and longer follow-up period are mandatory to verify and enhance our results.
Second, all patients in this study had sustained VT and cardiac sarcoidosis. These data do not apply to and cannot be extrapolated to all patients with cardiac sarcoidosis but rather only to those who have documented sustained VT. Third, new modalities such as MRI or positron emission tomography were not evaluated. Recently, use of late gadolinium enhancement and T2-weighted MRI and 18F-fluorodeoxyglucose positron emission tomography for the detection of occult granuloma sites and residual sarcoidosis activity was reported. 18, 19 Combined use of these multimodality techniques with gallium uptake may enhance prediction of corticosteroid effectiveness for VT recurrence. Late gadolinium enhancement MRI might have contributed to identification of patients requiring epicardial access.
Fourth, epicardial mapping was not performed in our patients, so we could not confirm entire critical circuits in some patients with scar-related VTs. For example, in 1 patient with recurrence of scar-related VT, entire endocardial activation mapping during VT showed a centrifugal pattern, and total activation time was much shorter than the VT cycle length. These findings could indicate existence of a re-entry circuit on the epicardial side of the akinetic/hypokinetic area. Epicardial ablation was recently reported to successfully eliminate recurrent VT after failure of endocardial ablation. 20 The systematic use of epicardial mapping and ablation might improve RFCA results in patients with VT associated with cardiac sarcoidosis. Furthermore, the VT circuit of sarcoidosis-related VT could exist in the intramural portion of the septum or free wall, possibly requiring chemical ablation, needle ablation, or bipolar ablation to eliminate all VT circuits. Finally, we showed that a Purkinje potential was present at a successful ablation site; however, this did not totally prove that the Purkinje system was the origin of the VT.
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